Related by context. All words. (Click for frequent words.) 67 CYP#C# [001] 66 genetic polymorphisms 65 VKORC1 65 Teriflunomide 64 K ras mutations 63 pharmacodynamic effects 63 SLC#A# [002] 63 plasma pharmacokinetics 63 dose proportionality 63 pharmacodynamic properties 63 serum phosphorous 63 EGFR mutation status 63 NPM1 mutation 62 HER2 expression 62 riociguat 62 obstructive coronary artery 62 APOE genotype 62 Subgroup analyzes 62 conditional logistic regression 62 glomerular filtration 62 causal variants 62 poststroke depression 62 LRP5 62 Non inferiority 62 aldosterone antagonist 61 neuropsychiatric symptoms 61 hsCRP 61 platelet reactivity 61 bezafibrate 61 Tasigna prolongs 61 bronchial hyperresponsiveness 61 pharmacokinetic interactions 61 thrombotic complications 61 tumor histology 61 preclinically 61 DNA methylation patterns 61 Akt activation 61 KRAS mutation 61 lactate dehydrogenase LDH 61 breast cancer subtypes 61 pharmacokinetics PK 61 Zevalin consolidation 61 Logistic regression 61 metastatic neuroendocrine tumors 61 antiplatelet medications 61 hyperalgesia 61 KRAS mutations 61 poor metabolizers 61 prognostic marker 61 platelet function 61 CYP#C# [002] 61 serum biomarkers 60 NAbs 60 PITX2 methylation 60 INVEGA ® 60 hematological parameters 60 Subgroup analysis 60 ABCB1 60 STRIDE PD 60 CYP#D# genotype 60 ImmuKnow 60 multivariate logistic regression 60 Darapladib 60 pharmacodynamic parameters 60 pharmacokinetic equivalence 60 antitumor effect 60 antidepressant efficacy 60 cardioprotective effects 60 teriflunomide 60 Cardiotoxicity 60 CYP#C# gene 60 CSF biomarkers 60 cystatin C 60 PR interval prolongation 60 CYP#A# CYP#D# 60 unmeasured confounders 60 postprandial hyperglycemia 60 KRAS status 60 statin cholesterol lowering 60 MAGE A3 ASCI 60 MET amplification 60 subclinical hypothyroidism 60 Observational studies 59 prostate cancer CaP 59 serum calcium 59 Chest x rays 59 p# activation 59 coxibs 59 unmeasured factors 59 DNA methylation markers 59 underlying pathophysiology 59 anti JCV antibodies 59 Genetic variants 59 renal toxicity 59 fulvestrant 59 impaired endothelial 59 sarcosine 59 ADPKD 59 Hp2 2 59 IKAROS alterations 59 convergent validity 59 pleiotropic effects 59 CYP#D# 59 hematopoietic cancers 59 genes CYP#C# 59 cerebral microbleeds 59 Dr. Gurbel 59 #F FDG PET 59 QTc prolongation 59 chronic lyme 59 histological subtype 59 tigecycline 59 clomipramine 59 BEXXAR Therapeutic Regimen 59 analgesic efficacy 59 extrapyramidal symptoms 59 PLX STROKE targeting 59 paricalcitol 59 c reactive protein 59 nonadherence 59 MGUS 59 chromium picolinate supplementation 59 mitochondrial toxicity 59 FCGR3A 59 bronchodilatory 59 inflammatory biomarkers 59 Lp PLA2 59 thyrotropin 59 left ventricular diastolic 59 immunohistochemical 59 SSc 59 cardiac conduction 59 liver histology 59 CYT# potent vascular disrupting 59 troponin T 59 thromboembolic complications 59 genetic loci 59 EXJADE 59 impaired insulin secretion 59 C. pneumoniae 59 NUCYNTA ™ 59 dosage regimens 59 progesterone receptor PR 58 cardiac troponin T 58 HIV HCV coinfected 58 SPARCL 58 hypermethylated 58 hsCRP levels 58 gene polymorphisms 58 serum urate levels 58 subgroup analyzes 58 airway hyperresponsiveness 58 hereditary predisposition 58 fibrate drugs 58 Multiple logistic regression 58 HMG CoA reductase 58 preserved systolic 58 APOE e4 58 venlafaxine XR 58 HER2 overexpression 58 histone deacetylases 58 narcolepsy cataplexy 58 IgG antibody 58 NATRECOR ® 58 HIV tropism 58 euthymic patients 58 albuminuria 58 pharmacodynamic PD 58 angiographically 58 S. maltophilia 58 hepatic lesions 58 Hurthle cell 58 adrenal function 58 perfusion MRI 58 genotypic resistance 58 antitumor efficacy 58 Cathepsin B 58 T2DM 58 coinfected patients 58 platelet inhibition 58 surrogate endpoint 58 SR B1 58 cardiac toxicity 58 residual confounding 58 somatostatin analog 58 safety tolerability pharmacokinetic 58 glycated hemoglobin levels 58 pharmacodynamics PD 58 ConclusionThis 58 ACCORD Lipid 58 occipital regions 58 deCODE AF TM 58 Endothelial dysfunction 58 IgG isotype 58 TGFBR1 * 6A 58 GABRA2 58 neurocognitive impairment 58 coagulation abnormalities 58 impair fertility 58 subclinical atherosclerosis 58 serum creatinine levels 58 clinico pathological 58 beta carotene supplementation 58 biologic pathways 58 immunological responses 58 CNTNAP2 58 silent myocardial ischemia 58 cryptogenic 58 mutational status 58 pathophysiological effects 58 diabetic kidney 58 statin simvastatin 58 pentoxifylline 58 bronchopulmonary dysplasia BPD 58 aminotransferase levels 58 dyslipidaemia 58 intravenous bisphosphonates 58 prognostic significance 58 CYP #A# 58 hepatic fibrosis 58 POAG 58 oxcarbazepine 58 GAMMAGARD 58 serum leptin 58 drug eluting stent implantation 58 MetAP2 58 carotid plaque 58 B7 H3 58 TNF antagonist 58 familial clustering 58 TPMT 58 LAB CGRP 58 juvenile idiopathic arthritis 58 stratifying patients 58 clinically meaningful differences 58 antioxidant supplementation 58 prolactin levels 58 Multivariate logistic regression 58 serum BDNF 58 virological response 57 MDRD equation 57 prostate carcinogenesis 57 Fetal heartbeats 57 BRAF mutation 57 oral antiplatelet agent 57 androgen depletion 57 thyroglobulin 57 Logistic regression analysis 57 Hormone receptor 57 chromosome #p#.# 57 BCL#A 57 plasma lipid 57 hematologic parameters 57 coronary stenosis 57 reactogenicity 57 ATACAND 57 exhaled nitric oxide 57 elevated homocysteine 57 serum potassium 57 apolipoprotein B 57 BMPR2 57 BCR ABL mutations 57 Oral NKTR 57 SOD2 gene 57 Coronary artery calcium 57 sorafenib tablets 57 thymidylate synthase 57 mTOR kinase 57 PNH patients 57 tolerability pharmacokinetics 57 IDH1 mutation 57 ursodeoxycholic acid 57 susceptibility loci 57 KIAA# 57 CD# expression [002] 57 Lymph node 57 relapsed MM 57 immunohistochemical analysis 57 Erectile function 57 unresectable tumors 57 creatinine levels 57 calcium antagonists 57 AST ALT 57 antiangiogenic therapy 57 heparanase 57 Vidaza ® 57 plasma kallikrein 57 cTnT 57 carbonic anhydrase inhibitors 57 HOMA IR 57 thyrotropin levels 57 etiologic 57 ADAS Cog 57 endometrial hyperplasia 57 RBP4 levels 57 #q# deletion 57 antiviral efficacy 57 silent ischemia 57 VerifyNow 57 LMN cream 57 pain palliation 57 SMAD4 57 confounder 57 MGd 57 ADCS CGIC 57 Multiple linear regression 57 sulphonylureas 57 fatty acid synthase 57 multivariate Cox 57 GPC5 57 SNP rs# [002] 57 antiplatelet therapies 57 squamous cell lung cancer 57 NAFLD 57 molecular biomarkers 57 postoperative delirium 57 microbleeds 57 chromosomal aberrations 57 psychosocial variables 57 PRIMO CABG2 57 KIF6 carriers 57 chromosomal rearrangement 57 carotid bruit 57 hepatotoxic 57 β blockers 57 Multivariate analysis 57 OGG1 57 susceptibility gene 57 newer atypical antipsychotics 57 monoamine neurotransmitters 57 inhibiting COX 57 hemostatic efficacy 57 intact parathyroid hormone 57 analgesic effects 57 MSH2 57 experimentally induced 57 tamoxifen metabolism 57 Celecoxib 57 differential gene expression 57 K ras mutation 57 lowering triglyceride levels 57 inhibit platelet function 57 aminotransferases 57 protease inhibitor mutations 57 microalbuminuria 57 fibrotic disease 57 Her2/neu 57 cardiac autonomic 57 atherogenic dyslipidemia 57 hepatic toxicity 57 neurocognitive function 57 LV dysfunction 57 elevated triglyceride levels 57 nicardipine 57 VerifyNow P#Y# Test 57 modifier genes 57 unstable detrusor muscle 57 Index CDAI 57 ADAGIO study 57 Scale cognitive subscale 57 intracranial stenosis 57 TRIOLEX HE# APOPTONE HE# 57 biologic plausibility 57 serum aminotransferase levels 57 KRAS mutation status 57 methylation patterns 57 underlying molecular mechanisms 57 transfusion syndrome 57 Previous epidemiological studies 57 alexithymia 57 EGFR expression 57 proton MR spectroscopy 57 biochemical abnormalities 57 apoE4 57 pressor response 57 PITX2 57 Tumor Response 57 carotid stenosis 57 carotid IMT 57 eosinophil count 57 inhaled TPI ASM8 56 apneic episodes 56 Relapsing remitting MS 56 endothelin antagonists 56 hyperphenylalaninemia HPA due 56 Aggrastat ® tirofiban hydrochloride 56 serum cotinine 56 r hGH 56 reduce serum phosphate 56 TOP2A 56 Pharmacokinetic studies 56 HIV coinfected 56 abnormal lipids 56 BRAF gene 56 ZYBRESTAT fosbretabulin 56 PsA 56 tumor subtypes 56 Suicidal ideation 56 HER2 positivity 56 logistic regression models 56 renal scarring 56 microvascular disease 56 antiarrhythmic 56 left ventricular systolic 56 myeloproliferative diseases 56 erythropoietic 56 pharmacogenetic tests 56 elevated CRP 56 hypericin 56 IL#B 56 plasma renin activity 56 spermidine 56 Kaplan Meier curve 56 lipid abnormalities 56 FGFs 56 Homocysteine 56 CIPN 56 hepatic function 56 RSD# oral 56 viral tropism 56 potent topoisomerase II 56 premorbid 56 FUS protein 56 effector function 56 LQTS 56 EGFR mutation 56 intensive statin therapy 56 hyperprolactinemia 56 eTag assays 56 flavopiridol 56 FGFR2 56 intracerebral haemorrhage 56 hormone receptor status 56 serum concentrations 56 PDE#A 56 nonalcoholic steatohepatitis NASH 56 interleukin IL -# 56 endoxifen 56 chemosensitivity 56 transient elastography 56 genetic biomarkers 56 NPH insulin 56 antithrombotic 56 ACTEMRA TM 56 prognostic markers 56 cTnI 56 eplerenone 56 epithelial tumors 56 TCF#L# gene 56 GRNOPC1 contains 56 intraobserver 56 nicotinic acid 56 orofacial clefts 56 decompensated liver disease 56 CTEPH 56 QT interval prolongation 56 atypical neuroleptics 56 prospectively defined 56 angiotensin converting enzyme inhibitors 56 antiangiogenic activity 56 plasma triglycerides 56 REMINYL ® 56 receptor subtypes 56 Poly ICLC 56 histone acetylation 56 procalcitonin 56 LHRH receptor 56 PGI2 56 NIHSS score 56 Sentinel Lymph Node Biopsy 56 florbetaben 56 antiphospholipid antibodies 56 prospectively stratified 56 endophenotypes 56 Cognitive impairment 56 BENICAR HCT 56 symptomatic pulmonary embolism 56 multiple logistic regression 56 Squamous 56 serum GGT 56 conventional antipsychotics 56 PSADT 56 trans palmitoleate 56 nonfasting triglyceride levels 56 percutaneous biopsy 56 Multivariate analyzes 56 immunomodulation 56 ToGA 56 perioperatively 56 CYP#D# gene 56 pharmacodynamic profile 56 ventricular tachyarrhythmia 56 HMG CoA reductase inhibitor 56 Cardiorespiratory fitness 56 predisposing factor 56 thyroid deficiency 56 tarenflurbil 56 normal physiologic 56 PTEN mutations 56 bioequivalency 56 anti androgen 56 gadobutrol 56 lipoprotein levels 56 chlorthalidone 56 creatinine clearance CrCl 56 rs# [002] 56 KIF6 gene 56 linear pharmacokinetics 56 liver metastasis 56 HAQ DI 56 Univariate analysis 56 molecular abnormalities 56 chlamydial infection 56 serum calcium levels 56 genetic variants associated 56 selenium supplementation 56 vascular blockages 56 recurrent VTE 56 clinicopathological features 56 SNP rs# [001] 56 Epidemiologic studies 56 Corus CAD 56 hs CRP 56 Arterial stiffness 56 symptomatic VTE 56 Immunohistochemical 56 Outpatient Setting 56 APTIVUS r 56 HBsAg 56 proteinuria 56 VaD 56 fusion enhancers 56 advanced adenomas 56 armodafinil 56 S/GSK# 56 R# #mg BID 56 serum cholesterol 56 Pseudomonas aeruginosa infections 56 predictive validity 56 graft dysfunction 56 colorectal adenoma 56 HRQL 56 EMBLEM TM 56 nephrotoxicity 56 ruboxistaurin 56 Estrogen Receptor 56 periprocedural MI 56 colesevelam 56 Uncontrolled hypertension 56 comorbid disorders 56 gene loci 56 basal bolus regimen 56 C Reactive Protein 56 glycated hemoglobin HbA1c 56 Valproic acid 56 SGRQ 56 probiotic supplementation 56 thromboembolic events 56 QT prolongation 56 prostate cancer PCa 56 neurodevelopmental outcome 56 elevated IOP 56 co receptor tropism 56 pharmacologic intervention 56 CTAP# Capsules 56 COMT genotype 56 Pharmacokinetic 56 WT1 56 ZACTIMA 56 VADT 56 haematologic 56 dyslipidemia abnormal 56 Ribavirin causes 56 pharmacodynamic biomarkers 56 atherothrombotic disease 56 paclitaxel eluting stents 56 metabolite concentrations 56 Cotinine 56 thromboembolic 56 MS relapses 56 UGT#A# 56 artery stenosis 56 efficacy tolerability 56 TRAIL induced apoptosis 56 myelofibrosis polycythemia vera 56 donepezil 56 antiplatelet drugs 55 confirmatory clinical 55 pyridostigmine 55 serotonin receptor 55 aMCI precursor 55 endocannabinoid signaling 55 Symptom severity 55 Chronic pancreatitis 55 ZNF# 55 Randomized clinical trials 55 2 diabetes T2D 55 pharmacokinetic parameters 55 #beta HSD 1 55 EDEMA3 trial 55 amisulpride 55 clinicopathological 55 tumor subtype 55 hepatic liver 55 EoE 55 systolic dysfunction 55 oseltamivir resistance 55 sonographic diagnosis 55 undergo prostate biopsy 55 salivary cortisol 55 serum creatinine 55 MIF protein 55 infarct size 55 HPA axis 55 Disease Severity 55 elevated ALT 55 hypercholesterolaemia 55 transrectal ultrasound guided 55 intima media thickness 55 EGFR mutations 55 adrenal suppression 55 androgen signaling 55 postoperative complication 55 #HT#A partial agonist 55 FDG-PET/CT 55 promoter methylation 55 physiologic mechanisms 55 breast carcinomas 55 genotoxicity 55 platelet aggregation 55 urate lowering 55 Prehypertension 55 ascertainment bias 55 clinically insignificant 55 Avandia Actos 55 secretory phospholipase A2 55 variant angina 55 kidney urologic 55 acute porphyria 55 Metastatic colorectal cancer 55 serum phosphate 55 ExTRACT TIMI 55 HER2 gene 55 fetuin 55 lymph node metastases 55 atherosclerotic lesions 55 metabolic parameters 55 BARI 2D 55 CPAP adherence 55 generalizability 55 abdominal adiposity 55 monoclonal gammopathy 55 clusterin 55 HMGCR 55 PCa 55 OnDose TM 55 perioperative complications 55 pharmacodynamic markers 55 postoperative pulmonary 55 hypercalciuria 55 Lenocta TM sodium stibogluconate 55 CP CPPS 55 SSRI citalopram 55 genetic determinants 55 CA9 SCAN 55 ovarian hormones 55 patriotism Gration 55 EBV infection 55 EGFr expressing metastatic colorectal 55 prehospital setting 55 glucocorticoid receptors 55 serum testosterone 55 exploratory endpoints 55 familial pancreatic cancer 55 demyelinating 55 achieved statistical significance 55 macrovascular disease 55 nondiabetics 55 genetic polymorphism 55 angiotensin II receptor blockers 55 cobiprostone 55 anti angiogenic drugs 55 Clusterin 55 prognostic variables 55 Bacterial vaginosis 55 Kinoid 55 subclinical hyperthyroidism 55 PCNSL 55 pituitary hormone 55 Atomoxetine 55 prognostic indicators 55 AAT deficiency 55 serum phosphate levels 55 unfavorable cytogenetics 55 CIMZIA TM certolizumab pegol 55 DLQI 55 ovarian endometrial 55 univariate 55 plasma folate 55 pharmacodynamic profiles 55 endothelial dysfunction 55 vasogenic edema 55 nodal metastasis 55 glial tumors 55 node metastases 55 opioid naive 55 estimated glomerular filtration 55 Viral load 55 psychiatric comorbidities 55 KRAS oncogene 55 Haptoglobin 55 ORMDL3 55 contrast echocardiography 55 pulmonary toxicity 55 prognostic indicator 55 weekly CSBMs 55 unmeasured confounding 55 dosing frequency 55 atherothrombotic 55 cardiovascular morbidity 55 nucleotide analog 55 tHcy 55 Exacerbations 55 diagnostic modality 55 autonomic dysfunction 55 FDG PET imaging 55 visceral adiposity 55 angiotensin receptor blockers ARBs 55 urate 55 serum uric acid 55 antihypertensive drugs 55 heterozygotes 55 PTEN gene 55 prospective multicentre 55 TMPRSS2 ERG fusion 55 antibody titer 55 relapsed SCLC 55 transgene expression 55 postoperative mortality 55 Arranon 55 hypoperfusion 55 mu opioid agonists 55 PTPN# 55 affective psychosis 55 dopaminergic therapy 55 SYNTAX trial 55 MSMB 55 glucose homeostasis 55 myocardial reperfusion 55 ginkgo extract 55 lipid concentrations 55 pressure natriuresis 55 testosterone supplementation 55 Poisson regression 55 nonrandomized 55 CSF Tf 55 included exfoliative dermatitis 55 cardioprotective effect 55 apolipoprotein E4 55 circadian clock genes 55 HbA1C 55 hypersensitivity allergic reactions 55 orally inhaled migraine 55 safety tolerability pharmacokinetics 55 ELISpot 55 osteopontin 55 ADAM# 55 pretransplant 55 LTBI 55 mutated K ras 55 adrenal cortex 55 deCODE BreastCancer TM 55 Fibrates 55 galectin 3 55 biodistribution 55 coronary endothelial 55 active comparator 55 antipsychotic efficacy 55 nitrotyrosine 55 5 HTTLPR 55 cardiovascular calcification 55 subclinical disease 55 varespladib 55 chromosome aberrations 55 clinically meaningful improvements 55 injectable investigational 55 BoNTA 55 randomized controlled trials RCTs 55 conventional DMARDs 55 SORL1 55 CMV reactivation 55 Sjögren syndrome 55 EEG abnormalities 55 urate levels 55 GBA mutations 55 intracellular uptake 55 ELISPOT assay 55 STRATEGY FOR AN OPEN 55 Torsades de Pointes 55 miRview ™ squamous 55 IgE antibody 55 aldosterone hormone 55 conventional angiography 55 CANCIDAS 55 adiponectin levels 55 glomerular filtration rate 55 lipid parameters 55 baseline HbA1c 55 HBV infections 55 alanine aminotransferase ALT 55 invasive lobular 55 bile acid metabolism 55 antihypertensive therapy 55 aMCI 55 somatostatin 55 serum triglycerides 55 avosentan 55 serum lipid 54 inhaled iloprost 54 Dr. Pasinetti 54 coronary calcification 54 oncologic outcomes 54 thiopurine 54 CETP inhibition 54 ALT flares 54 DAS# remission 54 skin sterol 54 SORT OUT III 54 cyclic AMP cAMP 54 sirolimus eluting stents 54 tamoxifen Nolvadex ® 54 VEGFR1 54 folic acid vitamin B6 54 CLA supplementation 54 FUSILEV enhances 54 Alpha synuclein 54 cranial irradiation 54 vascular endothelial dysfunction 54 Tekamlo 54 amyloid deposition 54 Mohats demanded 54 cisplatin resistant 54 prognostic biomarker 54 hyperacute 54 CDK8 54 neurologic symptoms 54 glycosylated hemoglobin HbA1c 54 lipoprotein 54 gp# protein [002] 54 intensive lipid lowering 54 hypercoagulable 54 neurocognitive deficits 54 hepatocellular carcinomas 54 serologic 54 axillary lymph node 54 neutrophil counts 54 benign moles 54 ACh 54 MAPK pathway 54 secondary efficacy endpoints 54 malignant lesions 54 GSTT1 54 antiandrogens 54 MMP inhibitors 54 CD#c 54 pathogenic mechanisms 54 logistic regression analysis 54 insulin sensitizers 54 unruptured aneurysm 54 SE alleles 54 complete cytogenetic response 54 cerebral oxygenation 54 APTIVUS R 54 IUGR 54 OSAHS 54 autoregulation 54 immunofluorescent 54 chloride secretion 54 intravascular hemolysis 54 microvascular syndrome 54 anticancer activity 54 viral kinetics 54 coadministration 54 vasodilators 54 PREVENT IV 54 LVNC 54 mg metformin 54 APOL1 54 EchoCRT 54 myocardial viability 54 allele frequencies 54 problem Bellau 54 perfusion abnormalities 54 Vectibix monotherapy 54 carotid atherosclerosis 54 gp# vaccine 54 Diovan HCT 54 serum clusterin levels 54 N glycan 54 vasomotor symptoms 54 pancreatic endocrine 54 immunologic responses 54 subcutaneous PRO 54 logistic regression analyzes 54 FeNO 54 Peripheral edema 54 serotonin transporter 54 RoACTEMRA 54 Alzheimer Disease Assessment 54 T2D 54 HCV replication 54 MMSE score 54 meta regression 54 cytotoxicity 54 sCJD 54 Evidence Therapeutic study 54 tissue oxygenation 54 renal cell carcinomas 54 NPM1 mutations 54 alicaforsen enema 54 prognostically 54 ptau 54 Thiazolidinediones 54 plasma leptin 54 Afatinib 54 monogenic 54 phenothiazines 54 artery elasticity 54 Acute pancreatitis 54 Vitamin D insufficiency 54 serum urate 54 drug metabolizing enzymes 54 NMP# protein 54 Val HeFT 54 hypothalamic pituitary adrenal axis 54 thromboembolic disease 54 limiting toxicity 54 #.#ng/ml 54 antiproliferative effects 54 chromosomal alterations 54 glomerular 54 endoscopic gastric ulcers 54 causative mutations 54 triglyceride concentrations 54 p# biomarker 54 protein kinase C 54 morphometric vertebral fractures 54 Brugada syndrome 54 Cystatin C 54 TEAEs 54 EphB2 levels 54 recombinant PSMA vaccine 54 Helicobacter pylori infection 54 Hematologic toxicity 54 vismodegib 54 primary cilia 54 FDG PET scans 54 GSTP1 54 therapeutic regimens 54 ThermoDox ® clinical 54 N acetylcysteine 54 dopamine transporter 54 obstructive CAD 54 residual platelet reactivity 54 dermatologic reactions 54 transferrin saturation 54 angina myocardial infarction 54 Multiple Proteases And 54 inactivated strain 54 chromosomal mutations 54 spirometric 54 reboxetine 54 esophageal squamous cell carcinoma 54 abnormal cytology 54 CD# expression [001] 54 Coronary angiography 54 serum albumin 54 BRAF inhibitor 54 IgA deficiency 54 virologic responses 54 dopamine neuron 54 Glucocorticoids 54 Primary endpoints 54 Atopic eczema 54 Aprotinin 54 blinded randomized placebo controlled 54 dexrazoxane 54 maximally tolerated dose 54 systemic toxicity 54 vicriviroc 54 microRNA expression 54 pathophysiologic 54 confounding variables 54 metabolomic profiling 54 intravenous CK # 54 siRNA knockdown 54 G6PD deficiency 54 quantitate 54 neuropsychological impairments